Search

Displaying results 9801 - 9810 of 10000 in total
  1. Drug

    Leptazoline A

    go.drugbank.com/drugs/DB15551
    Experimental

    Leptazoline A is a polar oxazoline from the Cyanobacterium Leptolyngbya sp. Also see [Leptazoline B], [Leptazoline C], and [Leptazoline D].

    Synonyms: Leptazoline A
  2. Drug

    Leptazoline B

    go.drugbank.com/drugs/DB15552
    Experimental

    Leptazoline B is a polar oxazoline from the Cyanobacterium Leptolyngbya sp. Also see [Leptazoline A], [Leptazoline C], and [Leptazoline D].

  3. Drug

    Leptazoline C

    go.drugbank.com/drugs/DB15553
    Experimental

    Leptazoline C is a polar oxazoline from the Cyanobacterium Leptolyngbya sp. Also see [Leptazoline A], [Leptazoline B], and [Leptazoline D].

  4. Drug

    Reloxaliase

    go.drugbank.com/drugs/DB15560
    Investigational

    Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from _Bacillus Subtilis_.

  5. Drug

    Echinomycin

    go.drugbank.com/drugs/DB15582
    Experimental

    Echinomycin is a cytotoxic polypeptide quinoxaline antibiotic isolated from _Streptomyces echinatus_ that binds to DNA and inhibits RNA synthesis.

    Synonyms: Quinomycin A
  6. Drug

    ORG-31710

    go.drugbank.com/drugs/DB15585
    Experimental

    ORG-31710 is a progestational hormone antagonist.

  7. Drug

    (5Z,7E,9)-decatrien-2-one

    go.drugbank.com/drugs/DB15619
    Investigational

    Similar to [(5E,7E,9)-decatrien-2-one], it has a strong pineapple aroma.[A191116]

  8. Drug

    Inolimomab

    go.drugbank.com/drugs/DB15628
    Investigational

    It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.[A241385]

  9. Drug

    Fluzoparib

    go.drugbank.com/drugs/DB15637
    Investigational

    Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).

  10. Drug

    Gusacitinib

    go.drugbank.com/drugs/DB15670
    Investigational

    Gusacitinib is under investigation in clinical trial NCT02550678 (A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma).